Organization (Nonprofit)
Aeras
ClinicalTrials.gov lists Aeras as lead sponsor of 23 trials. It has 1 active development program.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Aeras: 23 lead-sponsored trials and 1 legal-entity registration.
Disease areas (4)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Tuberculosis | 33 |
| Latent Tuberculosis | 3 |
| HIV Infections | 2 |
| Tuberculosis, Pulmonary | 2 |
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2018 | 1 |
| 2017 | 1 |
| 2015 | 2 |
| 2014 | 6 |
| 2013 | 3 |
| 2012 | 3 |
| 2011 | 4 |
| 2010 | 3 |
| 2009 | 4 |
| 2008 | 4 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: none of the 23 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| H56:IC31 | Tuberculosis | Phase 2 | 4 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 1 hit target (n=1) | 0 of 1 on time (n=1) |
Journals published in (17)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Vaccine | 8 |
| PloS one | 4 |
| The New England journal of medicine | 3 |
| American journal of respiratory and critical care medicine | 2 |
| The Journal of infectious diseases | 2 |
Showing 5 of 17 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2 | 1 | 2025-07-22 |
Organization relationships (19)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Statens Serum Institut | Co sponsors trial with | 9 |
| Sanofi Pasteur, a Sanofi Company | Co sponsors trial with | 4 |
| University of Oxford | Co sponsors trial with | 4 |
| Crucell Holland BV | Co sponsors trial with | 3 |
| University of Cape Town | Co sponsors trial with | 2 |
Showing 5 of 19 relationships.
Latest dated events (35)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-07-22 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2018-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2018-03-27 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2017-08-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2015-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 35 events.
Biomarker capability evidence (83)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| F2 | Trial sponsor | Named in trial exclusion criteria |
| F2 | Trial sponsor | Named in trial exclusion criteria |
| F3 | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 83 evidence rows.
On Scientist.com
Aeras is listed as a research supplier in the Scientist.com network.
Service areas
Aeras provides tuberculosis vaccine research, development, licensing, and manufacturing services.
- Website
- www.aeras.org
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Aeras on Scientist.com
For prices, more details, or to contact Aeras, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.